Atossa Genetics (ATOS) Earning Positive Media Coverage, AlphaOne Reports

Media coverage about Atossa Genetics (NASDAQ:ATOS) has been trending positive this week, according to AlphaOne Sentiment Analysis. The research group, a subsidiary of Accern, ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Atossa Genetics earned a media sentiment score of 0.27 on AlphaOne’s scale. AlphaOne also gave press coverage about the company an impact score of 76 out of 100, indicating that recent news coverage is likely to have an effect on the company’s share price in the near future.

Atossa Genetics (NASDAQ:ATOS) traded up 1.15% during trading on Friday, reaching $0.53. 33,947 shares of the company’s stock traded hands. Atossa Genetics has a 52-week low of $0.51 and a 52-week high of $5.70. The stock’s market cap is $2.01 million. The company’s 50 day moving average is $0.63 and its 200-day moving average is $1.30.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at

Atossa Genetics Company Profile

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

12 Month Chart for NASDAQ:ATOS

Receive News & Ratings for Atossa Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply